This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ekström, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ekström, N.

 Previous Article  |  Next Article 

Infection and Immunity, January 2005, p. 369-377, Vol. 73, No. 1
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.1.369-377.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial

Nina Ekström,* Heidi Åhman,{dagger} Jouko Verho, Jukka Jokinen, Merja Väkeväinen,{ddagger} Terhi Kilpi, Helena Käyhty, and the Finnish Otitis Media Study Group§

National Public Health Institute (KTL), Helsinki, Finland

Received 31 May 2004/ Returned for modification 29 June 2004/ Accepted 17 September 2004

The licensure of new pneumococcal conjugate vaccines (PCVs) relies on immunogenicity data. When defining correlates of protection, vaccine efficacy data must be included. In the FinOM Vaccine Efficacy Trial, the PncOMPC vaccine showed an efficacy profile similar to that of the licensed PncCRM vaccine despite different antibody responses after primary and booster vaccinations. We determined antibody kinetics and avidities in a subgroup of infants participating in the FinOM trial. A total of 166 infants in three vaccine groups were immunized at 2, 4, 6, and 12 months of age with 7-valent PCV, PncCRM or PncOMPC, or hepatitis B vaccine. Concentrations of serum immunoglobulin G (IgG) against pneumococcal capsular polysaccharides were determined at 2, 4, 6, 7, 12, 13, and 24 months of age, and the avidity index (AI) to serotypes 6B, 19F, and 23F were determined at 7, 12, 13, and 24 months of age by enzyme immunoassay. Both PCVs were highly immunogenic, but they demonstrated different kinetics of antibody response; the concentration of IgG against serotypes 6B, 19F, and 23F declined faster after the third and fourth doses of vaccine in the PncCRM group than in the PncOMPC group. For both PCVs, the mean AI of anti-6B and -23F, but not of anti-19F, increased during the follow-up, which is in line with serotype-specific protection in the FinOM trial. Our data suggest that the kinetics and avidities of antibodies should be considered, in addition to antibody responses, when defining correlates of protection.

* Corresponding author. Mailing address: Vaccine Immunology Laboratory, National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland. Phone: 358-9-4744 8902. Fax: 358-9-4744 8599. E-mail: nina.ekstrom{at}ktl.fi.

Editor: D. L. Burns

{dagger} Present address: Wyeth Nordic, Vantaa, Finland.

{ddagger} Present address: University of Texas Southwestern Medical Center, Dallas, Texas.

§ Contributing members of the Finnish Otitis Media Study Group are listed in Acknowledgments.

Infection and Immunity, January 2005, p. 369-377, Vol. 73, No. 1
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.1.369-377.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Melin, M., Jarva, H., Siira, L., Meri, S., Kayhty, H., Vakevainen, M. (2009). Streptococcus pneumoniae Capsular Serotype 19F Is More Resistant to C3 Deposition and Less Sensitive to Opsonophagocytosis than Serotype 6B. Infect. Immun. 77: 676-684 [Abstract] [Full Text]  
  • Clutterbuck, E. A., Oh, S., Hamaluba, M., Westcar, S., Beverley, P. C. L., Pollard, A. J. (2008). Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine. CVI 15: 182-193 [Abstract] [Full Text]  
  • Ekstrom, N., Vakevainen, M., Verho, J., Kilpi, T., Kayhty, H., the FinOM Study Group, (2007). Functional Antibodies Elicited by Two Heptavalent Pneumococcal Conjugate Vaccines in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 75: 1794-1800 [Abstract] [Full Text]  
  • Harris, S. L., Tsao, H., Ashton, L., Goldblatt, D., Fernsten, P. (2007). Avidity of the Immunoglobulin G Response to a Neisseria meningitidis Group C Polysaccharide Conjugate Vaccine as Measured by Inhibition and Chaotropic Enzyme-Linked Immunosorbent Assays. CVI 14: 397-403 [Abstract] [Full Text]  
  • Navarro, D., Escribano, A., Cebrian, L., Gimeno, C., Garcia-Maset, L., Garcia-de-Lomas, J., the Spanish Pneumococcal Infection Study Network, (2006). Type-Specific Antibodies to Pneumococcal Capsular Polysaccharide Acquired either Naturally or after Vaccination with Prevenar in Children with Underlying Chronic or Recurrent Lung Diseases. CVI 13: 665-670 [Abstract] [Full Text]  
  • Rose, M. A., Schubert, R., Strnad, N., Zielen, S. (2005). Priming of Immunological Memory by Pneumococcal Conjugate Vaccine in Children Unresponsive to 23-Valent Polysaccharide Pneumococcal Vaccine. CVI 12: 1216-1222 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»